Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)
NCT03188536 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 282
Last updated 2020-10-12
Summary
The purpose of this study is to characterize the multiple myeloma (MM) participants with symptomatic relapse and/or refractory disease in Spain.
Conditions
Interventions
- OTHER
-
No Intervention
As it was an observational study, no intervention was administered in this study.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Medical Monitor Clinical Science · Takeda
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-26
- Primary Completion
- 2018-11-15
- Completion
- 2019-01-30
Countries
- Spain
Study Locations
More Related Trials
-
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
NCT00530816 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
NCT05217082 ·Status: COMPLETED
-
Retrospective Study to Describe Carfilzomib Use on Patients With Relapsed Multiple Myeloma in France in the Context of Carfilzomib Nominative Expanded Access and Compassionate Use
NCT04811508 ·Status: COMPLETED
-
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318 ·Status: RECRUITING
-
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
NCT06767254 ·Status: RECRUITING
-
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT03361748 ·Status: COMPLETED ·Phase: PHASE2
-
Multiple Myeloma Patient Registry
NCT03180853 ·Status: TERMINATED
-
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
NCT04035226 ·Status: COMPLETED
-
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe
NCT03091127 ·Status: COMPLETED
-
Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma
NCT02394210 ·Status: TERMINATED
-
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
NCT03525678 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
NCT02116569 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
NCT06888856 ·Status: NOT_YET_RECRUITING
-
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT04975399 ·Status: TERMINATED ·Phase: PHASE1
-
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immune Profiling in Multiple Myeloma
NCT04135079 ·Status: COMPLETED
-
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
NCT05565807 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma
NCT05064358 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma
NCT05920876 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
NCT01775553 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
NCT03464916 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)
NCT04721002 ·Status: COMPLETED